<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35391602</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1590-3478</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>43</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title>
          <ISOAbbreviation>Neurol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Expanding the spectrum of SOX1-antibodies in neuropathy: the coexistence of anti-SOX1 and Guillain-Barré syndrome-a case report.</ArticleTitle>
        <Pagination>
          <StartPage>3979</StartPage>
          <EndPage>3982</EndPage>
          <MedlinePgn>3979-3982</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-022-06055-2</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">Antibodies against SOX1 (or anti-glial nuclear antibody, AGNA) are partially characterized onconeural antibodies, firstly described in association with small cell lung cancer (SCLC). Lambert-Eaton myasthenic syndrome is the most frequent paraneoplastic syndrome (PNS) found in patients with anti-SOX1-antibody positivity. Other associations are chronic axonal polyneuropathy, paraneoplastic limbic encephalitis, and paraneoplastic cerebellar degeneration.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We describe a case of Guillain-Barré syndrome (GBS) with classical demyelinating phenotype associated with a positivity for anti-SOX1-antibodies.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A therapy with intravenous immunoglobulin led to progressive clinical improvement. After 12 months, clinical and neurophysiological pictures showed complete recovery. A thorough paraneoplastic screening was negative for underlying tumors.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This is the first case of GBS associated with anti-SOX1-antibodies described in literature. Although the concept of paraneoplastic GBS is controversial, different cases have been reported and GBS is considered a non-classical paraneoplastic syndrome. Our case expands the anti-SOX1-antibody clinical spectrum with relevant implications for the clinical practice.</AbstractText>
          <CopyrightInformation>© 2022. Fondazione Società Italiana di Neurologia.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Coniglio</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Neurology Unit, Department of Biomedical, Metabolic and Neural Science, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Turchi</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Neurology Unit, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giovannini</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Neurology Unit, Department of Biomedical, Metabolic and Neural Science, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mazzoli</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Neurology Unit, Department of Biomedical, Metabolic and Neural Science, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meletti</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Neurology Unit, Department of Biomedical, Metabolic and Neural Science, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Neurology Unit, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vaudano</LastName>
            <ForeName>Anna Elisabetta</ForeName>
            <Initials>AE</Initials>
            <Identifier Source="ORCID">0000-0002-6280-7526</Identifier>
            <AffiliationInfo>
              <Affiliation>Neurology Unit, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy. annavaudano@googlemail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Italy</Country>
        <MedlineTA>Neurol Sci</MedlineTA>
        <NlmUniqueID>100959175</NlmUniqueID>
        <ISSNLinking>1590-1874</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C490906">SOX1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D055748">SOXB1 Transcription Factors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020275" MajorTopicYN="Y">Guillain-Barre Syndrome</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010257" MajorTopicYN="Y">Paraneoplastic Syndromes</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010523" MajorTopicYN="Y">Peripheral Nervous System Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055748" MajorTopicYN="N">SOXB1 Transcription Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Anti-SOX1-antibodies</Keyword>
        <Keyword MajorTopicYN="N">Case report</Keyword>
        <Keyword MajorTopicYN="N">Guillain-Barré syndrome</Keyword>
        <Keyword MajorTopicYN="N">Paraneoplastic syndrome</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>5</Hour>
          <Minute>6</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35391602</ArticleId>
        <ArticleId IdType="doi">10.1007/s10072-022-06055-2</ArticleId>
        <ArticleId IdType="pii">10.1007/s10072-022-06055-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Fokke C, Van Den Berg B, Drenthen J, Walgaard C, Van Doorn PA, Jacobs BC (2014) Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain 137:33–43. https://doi.org/10.1093/brain/awt285</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awt285</ArticleId>
            <ArticleId IdType="pubmed">24163275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt P, SillevisYedeler Ch, Verschuuren JJGM, Vincent A, Voltz R (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75:1135–1140. https://doi.org/10.1136/jnnp.2003.034447</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2003.034447</ArticleId>
            <ArticleId IdType="pubmed">15258215</ArticleId>
            <ArticleId IdType="pmc">1739186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A, Lang B, Dalmau J (2005) Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol 165:166–171</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2005.03.020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Tan J, Sun H, Liu Y, Guan W, Jia J, Wang Z (2020) Anti-sox1 antibodies in paraneoplastic neurological syndrome. J Clin Neurol 16:530–546. https://doi.org/10.3988/jcn.2020.16.4.530</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3988/jcn.2020.16.4.530</ArticleId>
            <ArticleId IdType="pubmed">33029958</ArticleId>
            <ArticleId IdType="pmc">7541980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arends S, Drenthen J, van den Bergh P, Franssen H, Hadden RDM, Islam B, Kuwabara S, Reisin RC, Shahrizaila N, Amino H, Antonini G, Attarian S, Balducci C, Barroso F, Bertorini T, Binda D, Brannagan TH, Buermann J, Casasnovas C, Cavaletti G, Chao CC, Dimachkie MM, Fulgenzi EA, Galassi G, Gutiérrez Gutiérrez G, Harbo T, Hartung HP, Hsieh ST, Kiers L, Lehmann HC, Manganelli F, Marfia GA, Mataluni G, Pardo J, Péréon Y, Rajabally YA, Santoro L, Sekiguchi Y, Stein B, Stettner M, Uncini A, Verboon C, Verhamme C, Vytopil M, Waheed W, Wang M, Zivkovic S, Jacobs BC, Cornblath DR, IGOS consortium (2022) Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: differences in methods and reference values. Clin Neurophysiol 13:S1388-2457(22)00011–6. https://doi.org/10.1016/j.clinph.2021.12.014</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinph.2021.12.014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajabally YA, Durand MC, Mitchell J, Orlikowski D, Nicolas G (2015) Electrophysiological diagnosis of Guillain-Barré syndrome subtype: could a single study suffice? J Neurol Neurosurg Psychiatry 86:115–9. https://doi.org/10.1136/jnnp-2014-307815</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2014-307815</ArticleId>
            <ArticleId IdType="pubmed">24816419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uncini A, Kuwabara S (2018) The electrodiagnosis of Guillain-Barré syndrome subtypes: where do we stand? Clin Neurophysiol 129:2586–2593. https://doi.org/10.1016/j.clinph.2018.09.025</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinph.2018.09.025</ArticleId>
            <ArticleId IdType="pubmed">30419502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Vogrig A, Muñiz-Castrillo S, Antoine JCG, Desestret V, Dubey D et al (2021) Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflammation 8. https://doi.org/10.1212/NXI.0000000000001014</Citation>
        </Reference>
        <Reference>
          <Citation>Sabater L, Titulaer M, Saiz A, Verschuuren J, Güre AO, Graus F (2008) SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 70:924–928. https://doi.org/10.1212/01.wnl.0000281663.81079.24</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000281663.81079.24</ArticleId>
            <ArticleId IdType="pubmed">18032743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berger B, Dersch R, Ruthardt E, Rasiah C, Rauer S, Stich O (2016) Prevalence of anti-SOX1 reactivity in various neurological disorders. J Neurol Sci 369:342–346. https://doi.org/10.1016/j.jns.2016.09.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2016.09.002</ArticleId>
            <ArticleId IdType="pubmed">27653921</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
